Affiliations 

  • 1 Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 2 Pediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 3 Children's Hospital 1, Ho Chi Minh City, Vietnam
  • 4 University of Health Sciences and National Pediatric Hospital, Phnom Penh, Cambodia
  • 5 Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
  • 6 National Hospital of Pediatrics, Hanoi, Vietnam
  • 7 YRGCARE Medical Centre, CART CRS, Chennai, India
  • 8 Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
  • 9 Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
  • 10 HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
  • 11 Hospital Raja Perempuan Zainab II, Kelantan, Malaysia
  • 12 Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
  • 13 Hospital Likas, Kota Kinabalu, Malaysia
  • 14 Penang Hospital, Penang, Malaysia
  • 15 The Kirby Institute, UNSW Australia, Sydney, Australia
  • 16 TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand
J Virus Erad, 2015;1(3):192-195.
PMID: 27076917

Abstract

After a median of 115.9 months of follow-up, 90% of 206 HIV-1-infected children in a cohort in Asia who initiated antiretroviral treatment (ART) with mono or dual nucleoside reverse transcriptase inhibitors were alive and had comparable immunological and virological outcomes as compared to the 1,915 children who had started with highly active antiretroviral regimens. However, these children had higher rates of treatment-related adverse events, opportunistic infections, and cumulative mortality, and were more likely to require protease inhibitor-containing regimens or other more novel ART-based regimens.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.